22nd January 2019 Content supplied by: Curetis AG
Ares Genetics Receives Funding for AI-powered Infectious Disease and Antibiotic Resistance Test
Ares Genetics GmbH has received funding from the Vienna Business Agency for the development of a prototype solution for the rapid, Next-Generation Sequencing-based diagnosis of pathogens and associated antibiotic resistances for patients suffering from severe infections. The total volume of the 2.5-year TRIPLE-A (Assay Development and Artificial Intelligence to Diagnose Antibiotic Resistant Infections) development project amounts to EUR 1.3 million.
Ares Genetics approach is based on high-resolution Next Generation Sequencing (NGS) technology in combination with a proprietary, artificial intelligence (AI) curated genetic pathogen and antibiotic resistance (AMR) reference database, ARESdb, for result interpretation. To this end, in September 2018 Ares started the development of the ARESupa Universal Pathogenome Assay, a single diagnostic test designed to detect any pathogen and associated drug resistances from any native patient sample. As engineering and in-silico assay design has further advanced since September 2018, the TRIPLE-A project funded by the Vienna Business Agency now aims to develop a laboratory prototype of ARESupa. Therefore, Ares Genetics is currently setting up ARESlab, a dedicated R&D and diagnostic service laboratory in Vienna, Austria, for in-house test development and initial commercialization in Europe.
Date Published: 22nd January 2019
Source article link: Curetis AG
Newly Isolated Intestinal Microbiota Strains
Priorclave Shows Latest Autoclave Advances